Search research articles
Contact Us
Filters
Showing results (131-140 of 209) with videos related to
Page
of 21
Sort By:
Haematologica
|
June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns
Robert Stuver, Zachary R Moore, Stefan K Barta, et al.
Blood Cancer Journal
|
June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
Sabela Bobillo, Erel Joffe, David Sermer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Caitlin M Stewart, Laure Michaud, Karissa Whiting, et al.
Blood Advances
|
August 19, 2025
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma
Swaminathan P Iyer, Neha Mehta-Shah, Ranjana H Advani, et al.
Blood
|
December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Oreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Blood
|
July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
Sabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Leukemia & Lymphoma
|
July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis
Efrat Luttwak, Edith Tama Robin, Esther Drill, et al.
The Lancet. Haematology
|
February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
Christopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Blood Advances
|
September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
Steven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
The New England Journal of Medicine
|
February 5, 2025
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i>
Karlo Perica, Nayan Jain, Michael Scordo, et al.
Page
of 21
Search research articles
Search
Showing results (131-140 of 209) with videos related to
Sort By:
Page
of 21
Haematologica
|
June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns
Robert Stuver, Zachary R Moore, Stefan K Barta, et al.
Blood Cancer Journal
|
June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
Sabela Bobillo, Erel Joffe, David Sermer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Caitlin M Stewart, Laure Michaud, Karissa Whiting, et al.
Blood Advances
|
August 19, 2025
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma
Swaminathan P Iyer, Neha Mehta-Shah, Ranjana H Advani, et al.
Blood
|
December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Oreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Blood
|
July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
Sabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Leukemia & Lymphoma
|
July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis
Efrat Luttwak, Edith Tama Robin, Esther Drill, et al.
The Lancet. Haematology
|
February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
Christopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Blood Advances
|
September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
Steven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
The New England Journal of Medicine
|
February 5, 2025
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i>
Karlo Perica, Nayan Jain, Michael Scordo, et al.
Page
of 21